RP

Respirent Pharmaceuticals Co

China - Chongqing
Pharmaceutical

Focus: Respiratory Medicines

Respirent Pharmaceuticals Co is a life sciences company focused on Respiratory Medicines.

NeurologyRespiratory
Open Jobs
0

Products & Portfolio (1)

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
fluticasone propionate and salmeterol
Post-LOE
INHALATION · POWDER
salmeterol. The mechanisms of action described below for the individual components apply to fluticasone propionate and salmeterol inhalation powder. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices. Fluticasone Propionate Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Inflammation is also a component in the pathogenesis of COPD. In contrast to asthma, however, the predominant inflammatory cells in COPD include neutrophils, CD8+ T-lymphocytes, and macrophages. The effects of corticosteroids in the treatment of COPD are not well defined and ICS and fluticasone propionate when used apart from fluticasone propionate and salmeterol inhalation powder are not indicated for the treatment of COPD. Salmeterol Xinafoate Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta 2 -agonists may have cardiac effects. The pharmacologic effects of beta 2 -adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglan
exacerbations of COPD in patients with a history of exacerbationsasthmachronic obstructive pulmonary disease+1 more
2026
30

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts
Founded: 2018
Portfolio: 1 approved product
Top TAs: Respiratory
Portfolio Health
Post-LOE1 (100%)
1 total products
Therapeutic Area Focus
Respiratory
1 marketed
Marketed
Pipeline